摘要
目的观察补肾解毒通络方联合甲氨蝶呤治疗活动期类风湿关节炎的临床疗效。方法将60例活动期类风湿关节炎患者随机分为治疗组和对照组,每组30例。对照组予甲氨蝶呤口服治疗,治疗组在对照组治疗措施基础上加用补肾解毒通络方。两组疗程均为3个月,观察临床疗效及不良反应,比较治疗前后关节疾病活动度评分(DAS28)、健康评分(HAQ)以及C反应蛋白(CRP)、血沉(ESR)等指标的情况。结果 1治疗组、对照组总有效率分别为75.86%和40.74%,组间临床疗效差异有统计学意义(P<0.05)。2治疗前后组内比较,两组DAS28、HAQ、ESR、CRP水平差异有统计学意义(P<0.05);组间治疗后比较,DAS28、HAQ、CRP水平差异有统计学意义(P<0.05)。3治疗组治疗期间未出现不良反应,对照组治疗期间出现1例不良反应。结论补肾解毒通络方联合甲氨蝶呤治疗活动期类风湿关节炎的疗效满意,可明显改善关节功能,且不良反应较少。
Objective To observe the clinical efficacy of ＂Bushen Jiedu Formula＂ and methotrexate in treating rheumatoid arthritis （RA） in active stage. Methods Sixty cases with RA were randomized into treatment group and control group, with 30 cases in each group. Control group was treated by methotrexate, and treatment group was added with ＂Bushen Jiedu Formula＂, with the course of 3 months. The clinical efficacy, adverse effect, and scores of DAS28, HAQ, CRP, and ESR were compared before and after treatment. Results （1） The total effective rate was 75.86% in the treatment group and 40.74% in the control group, with a difference between the two groups （P 〈 0. 05 ）. （2） In each group, there were significant differences in the levels of DAS28, HAQ, ESR and CRP between before and after treatment （ P 〈 0. 05 ） ; after treatment, significant differences were found in the levels of DAS28, HAQ and CRP between the two groups （ P 〈 0.05 ）. （3） No adverse effect was found in the treatment group during the therapeutic period, and one adverse event was found in the control group. Conclusion Combined ＂Bushen Jiedu Formula＂ and methotrexate has positive effect on rheumatoid arthritis. It can improve the function of joint, and has less adverse effects.
出处
《上海中医药杂志》
2014年第11期55-57,共3页
Shanghai Journal of Traditional Chinese Medicine
